Aged ; Antigens, CD19/metabolism* ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers ; Biopsy ; Bone Marrow/pathology ; Bone Marrow Cells/metabolism* ; Bone Marrow Cells/pathology ; Drug Resistance, Neoplasm ; Female ; Humans ; Immunophenotyping ; Leukocyte Common Antigens/metabolism* ; Lymphoma, Mantle-Cell/drug therapy ; Lymphoma, Mantle-Cell/metabolism* ; Lymphoma, Mantle-Cell/mortality* ; Lymphoma, Mantle-Cell/pathology ; Male ; Middle Aged ; Prognosis ; Recurrence ; Treatment Outcome
Keywords
Cancer stem cell ; bone marrow ; mantle cell lymphoma
Abstract
Mantle cell lymphoma has features of both indolent and aggressive non-Hodgkin lymphomas. Repeated relapses leading to treatment failure in patients with mantle cell lymphoma might suggest the presence of cancer stem cells. A small cell population with CD45+/CD19 - was previously reported to represent cancer stem cells. We evaluated the clinical relevance of CD45+/CD19 - cells in bone marrow of patients with mantle cell lymphoma (n = 20). A CD45+/CD19 - cell population was observed in newly diagnosed mantle cell lymphoma, and its percentage correlated with tumor cells in bone marrow (r = 0.832, p = 0.001) and score on the simplified mantle cell lymphoma prognostic index (r = 0.675, p = 0.016). After treatment, CD45+/CD19 - cells decreased (mean: 0.012%), and CD45+/CD19 - cells (0.276%) were higher at relapse or progression than at diagnosis. In conclusion, a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma.